Obiltoxaximab is a monoclonal antibody used for prophylaxis or treatment of inhalational anthrax. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin.
- Mechanism
- Curator reviewed
ETI-204 is an affinity-enhanced, de-immunized antibody, which means that its ability to bind to its target pathogen has been strengthened and that elements that might cause an immune response have been removed. ETI-204 targets and binds to Protective Antigen, which prevents the anthrax toxins from binding to and entering the cells in the body, thereby preventing death.
- Primary indication
- Investigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease.Curator reviewed · 2 structured indications
- Formula / weight
- 148000.0 Da
- First approval
- Canada, 2020 · United States, 2016
- Code names
- ETI-204
- Brand names
Resolves to
What you can answer from here — as of December 02, 2025
Which drugs share a target with Obiltoxaximab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account